Taysha Gene Therapies, INC 8-K filings

Taysha Gene Therapies has priced an underwritten public offering of common stock and pre-funded warrants to raise approximately $200 million in gross proceeds.

Taysha Gene Therapies reported Q1 2026 results, highlighting FDA alignment on the TSHA-102 Biologics License Application pathway and continued clinical trial progress for Rett syndrome.

Taysha Gene Therapies reported full-year 2025 financial results and provided a corporate update, highlighting significant progress in its TSHA-102 Rett syndrome program and a strong cash position.

Taysha Gene Therapies announced FDA Breakthrough Therapy designation for TSHA-102, finalized pivotal trial protocol, and increased its ATM offering to $212 million, alongside Q3 2025 financial results.

Taysha Gene Therapies has regained full global rights to its lead TSHA-102 program for Rett syndrome after its option agreement with Astellas expired.

Taysha Gene Therapies announced new supplemental data from its REVEAL Phase 1/2 trials for TSHA-102 in Rett Syndrome, showing 100% of patients achieved multiple functional gains.

Taysha Gene Therapies announced FDA Breakthrough Therapy Designation for TSHA-102 in Rett Syndrome and finalized its pivotal trial protocol, aiming for Q4 2025 enrollment.

Taysha Gene Therapies reported Q2 2025 financial results and significant progress in its TSHA-102 pivotal trial for Rett syndrome, extending its cash runway into 2028.

Taysha Gene Therapies, Inc. announced that its stockholders approved an amendment to increase the authorized number of common shares from 400 million to 700 million at its 2025 annual meeting, alongside the re-election of two directors and ratification of its independent auditor.

Taysha Gene Therapies has successfully priced a public offering of common stock and pre-funded warrants, raising approximately $200 million, while also announcing positive clinical data for its lead Rett syndrome gene therapy, TSHA-102, and alignment with the FDA on a pivotal trial design.

Taysha Gene Therapies announced written FDA alignment on the pivotal Part B trial design for TSHA-102 in Rett syndrome, supported by positive clinical data from Part A of its REVEAL trials showing a 100% responder rate.

Taysha Gene Therapies announced FDA alignment on a pivotal trial design for TSHA-102 in Rett syndrome, supported by positive clinical data from its REVEAL Part A trials and natural history data, while also suspending its $100 million ATM equity offering.

Taysha Gene Therapies announces FDA alignment on key trial elements for TSHA-102 and reports Q1 2025 financial results, highlighting progress in Rett syndrome treatment development.

Taysha Gene Therapies announced its full-year 2024 financial results and provided a corporate update, highlighting the progress of its TSHA-102 clinical program for Rett syndrome.

Taysha Gene Therapies announced positive clinical data for its TSHA-102 gene therapy in Rett syndrome, along with regulatory advancements and financial results for the third quarter of 2024.

Taysha Gene Therapies announced encouraging clinical data for its TSHA-102 gene therapy in Rett syndrome and secured $76.8 million in funding, extending its cash runway into Q4 2026.

Taysha Gene Therapies has announced the pricing of a public offering of common stock and pre-funded warrants, expected to generate approximately $75 million in gross proceeds.

Taysha Gene Therapies has commenced a public offering of up to $75 million of its common stock and pre-funded warrants, coinciding with positive updates from its ongoing clinical trials for Rett syndrome.

Taysha Gene Therapies reports positive clinical data from its REVEAL Phase 1/2 trials of TSHA-102 in Rett syndrome, showing improvements in both adult and pediatric patients.

Taysha Gene Therapies successfully held its 2024 annual meeting, electing two directors and ratifying its independent auditor.

Taysha Gene Therapies announced its first quarter 2024 financial results and provided a corporate update, highlighting progress in its TSHA-102 program for Rett syndrome.

Taysha Gene Therapies announced positive clinical updates for its Rett syndrome gene therapy program and reported full-year 2023 financial results, highlighting progress in clinical trials and financial improvements.